Episurf Medical to present at Redeye Theme Event: Commercialization in Life Science
Episurf Medical (Nasdaq: EPIS B) will attend Redeye Theme Event: Commercialization in Life Science which is held on March 20th, 2025. The event is arranged by Redeye and Episurf will be represented by its CEO Pål Ryfors. The format will be a 12-minute pitch followed by an 8-minute Q&A.
The presentation will be streamed live at 10:10 CET at: https://www.redeye.se/events/1073684/redeye-theme-commercialization-in-life-science-2 and will also be made available afterwards on our website www.episurf.com.
Location: Redeye, Mäster Samuelsgatan 42, Stockholm.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CET on 19 March 2025.</em></span></p>
[HtmlContact:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><strong><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">For more information, please contact:</span></strong></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Pål Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt;">Email: </span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
[HtmlTitle:protected] => <h1 style="line-height:120%"><span style="font-family:arial,helvetica,sans-serif"><strong>Episurf Medical to present at Redeye Theme Event: Commercialization in Life Science</strong></span></h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] =>
[Body:protected] => Episurf Medical (Nasdaq: EPIS B) will attend Redeye Theme Event: Commercialization in Life Science which is held on March 20th, 2025. The event is arranged by Redeye and Episurf will be represented by its CEO Pål Ryfors. The format will be a 12-minute pitch followed by an 8-minute Q&A.
The presentation will be streamed live at 10:10 CET at: https://www.redeye.se/events/1073684/redeye-theme-commercialization-in-life-science-2 and will also be made available afterwards on our website www.episurf.com.
Location: Redeye, Mäster Samuelsgatan 42, Stockholm.
[HtmlBody:protected] => <p style="margin-bottom:11px;margin-top:12px"><span><span style="font-size:11pt"><span><span style="font-family:arial,helvetica,sans-serif"><span style="font-size:10pt"><span><span style="color:black">Episurf Medical (Nasdaq: EPIS B) will attend Redeye Theme Event: Commercialization in Life Science which is held on March 20th, 2025. The event is arranged by Redeye and Episurf will be represented by its CEO Pål Ryfors. The format will be a 12-minute pitch followed by an 8-minute Q&A.<br>
<br>
The presentation will be streamed live at <strong>10:10 CET</strong> at: </span></span></span><a href="https://www.redeye.se/events/1073684/redeye-theme-commercialization-in-life-science-2" style="color:#0563c1; text-decoration:underline"><span style="font-size:10pt"><span>https://www.redeye.se/events/1073684/redeye-theme-commercialization-in-life-science-2</span></span></a> <span style="font-size:10pt"><span><span style="color:black">and will also be made available afterwards on our website </span></span></span><a href="https://www.episurf.com" style="color:#0563c1; text-decoration:underline"><span style="font-size:10pt"><span>www.episurf.com</span></span></a><span style="font-size:10pt"><span><span style="color:black">. </span></span></span><br>
<br>
<strong><span style="font-size:10pt"><span>Location</span></span></strong><span style="font-size:10pt"><span>: Redeye, Mäster Samuelsgatan 42, Stockholm.</span></span></span></span></span></span></p>
[ServiceCategories:protected] => Array
(
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CET on 19 March 2025.
[Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
[2] => Pål Ryfors
[3] => Episealer
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/4121228/3330223.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => Episurf Medical to present at Redeye Theme Event: Commercialization in Life Science - March 20
[Description:protected] => Episurf Medical to present at Redeye Theme Event: Commercialization in Life Science - March 20
[CreateDate:protected] => 2025-03-19T13:00:17.867Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 5010761
[EncryptedId:protected] => 27635F942CF45FE6
[IsRegulatory:protected] =>
[PublishDate:protected] => 2025-03-19T13:00:00Z
[LastChangeDate:protected] => 2025-03-19T13:00:17.85Z
[Title:protected] => Episurf Medical to present at Redeye Theme Event: Commercialization in Life Science
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/episurf-medical-to-present-at-redeye-theme-event--commercialization-in-life-science,c4121228
[LanguageVersions:protected] => Array
(
[0] => CisionBlockPro\Cision\LanguageVersion Object
(
[Code:protected] => sv
[ReleaseId:protected] => 5010759
)
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)